This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Roche Holding AG
Drug Names(s): R3487, MEM 3454, RO5313534
Description: MEM 3454 is a partial agonist of the nicotinic alpha-7 receptor. Alpha-7 nicotinic acetylcholine receptors are thought to be involved in memory, cognition, synaptic plasticity, and neuronal survival. They not only mediate cholinergic transmission but also influence signaling at noncholinergic synapses (such as glutamate and serotonin). In addition, they may mediate dopamine release in response to nicotine, particularly in the nucleus accumbens, part of the classic reward pathway.
RG3487 is also an antagonist of the 5-HT3 receptor. 5HT3 receptor antagonists are commonly used for the treatment of chemotherapy-induced nausea, but some studies have suggested utility in the treatment of schizophrenia symptoms as well.
Deal Structure: Roche has the right to obtain an exclusive license for MEM 3454 following the completion of Phase IIa clinical trials under Memory Pharmaceuticals' 2003 collaboration with Roche.
Memory Pharmaceuticals announced in October 2006 that Roche has elected to maintain itsoption to obtain an exclusive license for MEM 3454. This decision results in a $2 million milestone payment to Memory Pharmaceuticals.
Under the terms of the nicotinic alpha-7 alliance, Memory Pharmaceuticalsis responsible for the development of MEM 3454 through Phase IIa clinicaltrials. Roche has the right to obtain an exclusive license for MEM 3454following the completion of Phase IIa clinical trials for that compound. Rochemaintains this right through the development process by making three paymentsto Memory Pharmaceuticals upon its achievement of certain pre-establisheddevelopment milestones.
In June 2007, Memory Pharmaceuticals expanded its nicotinic alpha-7 receptor agonist agreement with Roche. Under the...See full deal structure in Biomedtracker
Additional information available to subscribers only: